Related Experiment Videos
Acute myocardial infarction and renal dysfunction: a high-risk combination
R Scott Wright1, Guy S Reeder, Charles A Herzog
1Division of Cardiology, Mayo Alliance for Clinical Trials, Mayo Clinic, Stabile 5, 150 Third Street SW, Rochester, MN 55902, USA. wright.scott@mayo.edu
Annals of Internal Medicine
|October 2, 2002
Summary
Patients with acute myocardial infarction (MI) and any level of renal disease face higher mortality risks. Those with renal failure receive less aggressive treatment, impacting survival outcomes.
Area of Science:
- Cardiology
- Nephrology
- Clinical Research
Background:
- Acute myocardial infarction (MI) poses a significant mortality risk for patients with severe renal disease.
- Outcomes for acute MI patients with mild to moderate renal insufficiency are less understood.
Purpose of the Study:
- To compare the outcomes of acute MI in patients with varying degrees of renal disease against those without renal failure.
- To analyze the impact of renal insufficiency on mortality following acute MI.
Main Methods:
- Retrospective cohort study involving 3106 patients admitted with acute MI.
- Patients were stratified into groups based on creatinine clearance, ranging from end-stage renal disease to no renal disease.
- Clinical characteristics, treatments, and survival rates (short- and long-term) were compared across strata.
Main Results:
- In-hospital mortality rates increased progressively with renal disease severity, from 2% (normal function) to 30% (end-stage renal disease).
- Adjusted analyses revealed significantly higher postdischarge death risks for all renal insufficiency groups compared to those without renal disease.
- Patients with renal failure received less frequent reperfusion and adjunctive therapies, while treatments like reperfusion, aspirin, and beta-blockers were associated with reduced postdischarge mortality.
Conclusions:
- Renal failure significantly increases the risk of death following acute MI.
- Patients with renal failure often receive less aggressive treatment compared to those with normal renal function, contributing to poorer outcomes.